摘要
目的研究新辅助化疗联合保乳术治疗Ⅱ、Ⅲ期乳腺癌的临床疗效。方法选取2016年3月—2017年3月收治的60例确诊患有乳腺癌的女性患者。随机分为观察组和对照组,给予对照组30例乳腺癌患者进行保乳术治疗,而观察组则在同对照组进行一样的保乳术治疗的基础上联用新辅助化疗进行治疗。观察两组患者的治疗情况。结果观察组的临床总有效率(93.30%)与对照组(73.33%)相比差异有统计学意义(P<0.05);且对患者治疗情况的满意程度进行调查,由调查结果可知,观察组的满意程度(86.7%)明显高于对照组(60.0%),两组比较差异有统计学意义(P<0.05)。结论新辅助化疗联合保乳术治疗,不仅有利于Ⅱ、Ⅲ期乳腺癌的恢复,而且乳腺癌患者在治疗过程中出现的不良反应较少,乳腺癌患者的配合治疗的积极性高,应在临床治疗过程中多加推广。
Objective To research the clinical curative effect of neoadjuvant chemotherapy and conservative surgery in treatment of breast cancer during the Ⅱ and Ⅲ periods. Methods 60 cases of females patients with breast cancer admitted and treated in our hospital from March 2016 to March 2017 were selected and randomly divided into two groups with 30 cases in each, the control group adopted the conservative surgery, while the observation group adopted the neoadjuvant chemotherapy and conservative surgery, and the treat-ment situation of the two groups was observed. Results The total clinical effective rate in the observation group were higher than that in the control group, [93.30% vs 73.33%], and the difference was statistically significant（P〈0.05）, and the satisfactory degree to the treatment was surveyed and the results showed that the satisfactory degree in the observation group was higher than that in the control group,（86.7% vs 60.0%）,and the difference between the two groups was statistically significant（ P〈0.05）. Conclusion Neoadjuvant chemotherapy and conservative surgery is conducive to the recovery of breast cancer during the Ⅱ and Ⅲ phases with fewer adverse reactions and high enthusiasm of breast cancer patients, and it should be widely promoted in the clinical treatment.
出处
《世界复合医学》
2017年第3期33-35,共3页
World Journal of Complex Medicine
关键词
新辅助化疗
保乳术
联合
Ⅱ、Ⅲ期乳腺癌
临床治疗
临床疗效
Neoadjuvant chemotherapy
Conservative surgery
Combined
Breast cancer during the Ⅱ and Ⅲ periods
Clinical treat-ment
Clinical curative effect
